Advertisement
Screener

Canopy Growth Corp (CGC) Overview

Canopy Growth Corp (CGC) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -0.03; Beat / miss (m).
  • 1 Oct 2025: Period ending 31 Dec 2025; Estimate (m); Actual -0.17; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -0.02; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -0.24; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$0.82$0.98$1.17$1.40$1.68$2.022025-09-292026-09-29$0.79$2.28$6.61$19.13$55.38$160.342021-09-292026-09-29$0.79$2.97$11.18$42.12$158.61$597.342016-09-292026-09-29$0.79$2.97$11.18$42.12$158.61$597.342014-04-072026-09-29$0.79$2.97$11.18$42.12$158.61$597.342014-04-072026-09-29

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$0.93
Previous close
$0.93
Change
$0.00
Change (%)
0.00%
Close date
2026-09-29
Previous close date
2026-09-28
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

CGC
-18.86%
S&P 500
(m)

1 year

CGC
-41.08%
S&P 500
(m)

3 years

CGC
-88.19%
S&P 500
(m)

5 years

CGC
-99.33%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

CAD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual -0.03

-0.97-0.69-0.41-0.120.1631 Dec 2024: estimate (m); actual -0.8931 Dec 2024(m)30 Jun 2025: estimate (m); actual -0.2430 Jun 2025(m)30 Sept 2025: estimate (m); actual -0.0230 Sept 2025(m)31 Dec 2025: estimate (m); actual -0.1731 Dec 2025(m)30 Jun 2026: estimate (m); actual -0.0330 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)-0.03(m)(m)
1 Oct 202531 Dec 2025(m)-0.17(m)(m)
1 Jul 202530 Sept 2025(m)-0.02(m)(m)
1 Apr 202530 Jun 2025(m)-0.24(m)(m)
1 Oct 202431 Dec 2024(m)-0.89(m)(m)

31 Mar 2026 ○ Estimate (m) ● Actual -0.88

-70.77-53.25-35.73-18.22-0.7031 Mar 2022: estimate (m); actual -7.9231 Mar 2022(m)31 Mar 2023: estimate (m); actual -70.6931 Mar 2023(m)31 Mar 2024: estimate (m); actual -9.2731 Mar 2024(m)31 Mar 2025: estimate (m); actual -4.7331 Mar 2025(m)31 Mar 2026: estimate (m); actual -0.8831 Mar 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202531 Mar 2026(m)-0.88(m)(m)
1 Apr 202431 Mar 2025(m)-4.73(m)(m)
1 Apr 202331 Mar 2024(m)-9.27(m)(m)
1 Apr 202231 Mar 2023(m)-70.69(m)(m)
1 Apr 202131 Mar 2022(m)-7.92(m)(m)

Revenue vs. Earnings

CAD

30 Jun 2026 ■ Revenue 81.17M ■ Earnings -14.58M — Profit margin -17.96%

-183.03M-218.2%-85.53M-147.6%11.97M-77.0%109.47M-6.5%30 Sept 2025: revenue 66.68M; earnings -4.98M; profit margin -7.47%30 Sept 202531 Dec 2025: revenue 74.54M; earnings -58.34M; profit margin -78.27%31 Dec 202531 Mar 2026: revenue 71.25M*; earnings -154.72M*; profit margin -217.17%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2026-01-01 to 2026-03-31; CAD.31 Mar 202630 Jun 2026: revenue 81.17M; earnings -14.58M; profit margin -17.96%30 Jun 2026

31 Mar 2026 ■ Revenue 0.28B ■ Earnings -0.26B — Profit margin -92.38%

-3.71B-984.7%-2.22B-686.9%-0.73B-389.1%0.77B-91.4%31 Mar 2023: revenue 0.33B; earnings -3.28B; profit margin -983.68%31 Mar 202331 Mar 2024: revenue 0.30B; earnings -0.69B; profit margin -233.45%31 Mar 202431 Mar 2025: revenue 0.27B; earnings -0.51B; profit margin -189.18%31 Mar 202531 Mar 2026: revenue 0.28B; earnings -0.26B; profit margin -92.38%31 Mar 2026

Revenue vs. Earnings

USD

No complete retained periods.

No complete retained periods.

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$0.93(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$0.93High(m)Average(m)Low(m)2025-09-292026-09-29

Recent news

View more →

(m)

YouTube videos mentioning CGC

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending (m).

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
(m)
Profit margin
(m)
Return on assets · 12 month
(m)
Stock compensation expense · all employees · 12 months
(m)
Index membership
(m)
Employees
205.00
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
2.04M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-4.34%*
Total return · month
-7.50%*
Total return · quarter
-6.57%*
Total return · half year
3.93%*
Total return · year to date
-18.86%*
Total return · 1 year
-41.08%*
Total return · 3 years
-88.19%*
Total return · 5 years
-99.33%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
(m)
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

Canopy Growth Corp Overview

View more →

(m)

(m)

SEC CIK
1737927
Industry (SIC)
2833 Medicinal Chemicals & Botanical Products
Country of operation
(m)
Business address
1 HERSHEY DRIVE, SMITH FALLS, K7A0A8
Fiscal year end
0331
Phone
855-558-9333

Similar stocks

Stock NameCountryMarket CapPE Ratio
USANA HEALTH SCIENCES INC (USNA)United States$0.264B-17.90
Niagen Bioscience, Inc. (NAGE)United States$0.238B15.72
Tilray Brands, Inc. (TLRY)United States$0.554B-5.97
FITLIFE BRANDS, INC. (FTLF)United States$0.087B16.59
MANNATECH INC (MTEX)United States$0.014B
NATURAL ALTERNATIVES INTERNATIONAL INC (NAII)United States$0.011B-1.16
Synergy CHC Corp. (SNYR)United States$0.001B
Functional Brands Inc. (MEHA)United States$0.001B
Cronos Group Inc. (CRON)$1.223B
Definium Therapeutics, Inc. (DFTX)United States$4.931B-17.87